Drugs / TRC003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07567521 | May 2026 → Dec 2027 expected | prostate cancer | C Ray Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRC003 | “TRC003 is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.” NCT07567521 ↗ |
| Action | Deplete | “emits radiation to kill them.” NCT07567521 ↗ |
| Modality | Other / unclassified | “TRC003 is a radioligand therapeutic agent” NCT07567521 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT07567521 ↗ |